company background image
IPH

Innate Pharma ENXTPA:IPH Stock Report

Last Price

€2.87

Market Cap

€228.8m

7D

-1.2%

1Y

-6.6%

Updated

28 May, 2022

Data

Company Financials +
IPH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

IPH Stock Overview

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally.

Innate Pharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Innate Pharma
Historical stock prices
Current Share Price€2.87
52 Week High€8.30
52 Week Low€2.44
Beta0.12
1 Month Change12.90%
3 Month Change-7.18%
1 Year Change-6.58%
3 Year Change-52.21%
5 Year Change-76.63%
Change since IPO-40.58%

Recent News & Updates

May 12
Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Shareholders in Innate Pharma S.A. ( EPA:IPH ) may be thrilled to learn that the analysts have just delivered a major...

Apr 13
Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...

Shareholder Returns

IPHFR BiotechsFR Market
7D-1.2%-0.4%3.7%
1Y-6.6%-39.4%-3.7%

Return vs Industry: IPH exceeded the French Biotechs industry which returned -39.4% over the past year.

Return vs Market: IPH underperformed the French Market which returned -3.7% over the past year.

Price Volatility

Is IPH's price volatile compared to industry and market?
IPH volatility
IPH Average Weekly Movement7.6%
Biotechs Industry Average Movement8.8%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: IPH is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: IPH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
1999215Mondher Mahjoubihttps://www.innate-pharma.com

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs.

Innate Pharma Fundamentals Summary

How do Innate Pharma's earnings and revenue compare to its market cap?
IPH fundamental statistics
Market Cap€228.84m
Earnings (TTM)-€45.48m
Revenue (TTM)€24.70m

9.3x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPH income statement (TTM)
Revenue€24.70m
Cost of Revenue€47.00m
Gross Profit-€22.30m
Other Expenses€23.18m
Earnings-€45.48m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 15, 2022

Earnings per share (EPS)-0.57
Gross Margin-90.28%
Net Profit Margin-184.10%
Debt/Equity Ratio38.6%

How did IPH perform over the long term?

See historical performance and comparison

Valuation

Is Innate Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.13x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPH's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: IPH is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: IPH is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPH is good value based on its Price-To-Book Ratio (2.1x) compared to the FR Biotechs industry average (2.8x).


Future Growth

How is Innate Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


61.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: IPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IPH's is expected to become profitable in the next 3 years.

Revenue vs Market: IPH's revenue (33% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: IPH's revenue (33% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IPH's Return on Equity is forecast to be high in 3 years time (21.7%)


Past Performance

How has Innate Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-29.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IPH is currently unprofitable.

Growing Profit Margin: IPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPH is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.

Accelerating Growth: Unable to compare IPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: IPH has a negative Return on Equity (-42.33%), as it is currently unprofitable.


Financial Health

How is Innate Pharma's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IPH's short term assets (€138.3M) exceed its short term liabilities (€79.9M).

Long Term Liabilities: IPH's short term assets (€138.3M) exceed its long term liabilities (€80.2M).


Debt to Equity History and Analysis

Debt Level: IPH has more cash than its total debt.

Reducing Debt: IPH's debt to equity ratio has increased from 1.7% to 38.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Innate Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Mondher Mahjoubi (63 yo)

5.42yrs

Tenure

€1,491,448

Compensation

Dr. Mondher Mahjoubi, M.D., serves as Chairman at PDC line Pharma SAS since June 2020. He has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016....


CEO Compensation Analysis

Compensation vs Market: Mondher's total compensation ($USD1.60M) is above average for companies of similar size in the French market ($USD412.98K).

Compensation vs Earnings: Mondher's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IPH's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: IPH's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Innate Pharma S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Innate Pharma S.A.
  • Ticker: IPH
  • Exchange: ENXTPA
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €228.840m
  • Shares outstanding: 79.74m
  • Website: https://www.innate-pharma.com

Number of Employees


Location

  • Innate Pharma S.A.
  • 117, Avenue de Luminy
  • BP 30191
  • Marseille
  • Provence-Alpes-Côte d'Azur
  • 13009
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.